Plasma volume expansion for suspected impaired fetal growth
- PMID: 10796166
- PMCID: PMC7045282
- DOI: 10.1002/14651858.CD000167
Plasma volume expansion for suspected impaired fetal growth
Abstract
Background: Failure of the normal expansion of plasma volume in the mother is associated with impaired fetal growth and pre-eclampsia.
Objectives: The objective of this review was to assess the effects of plasma volume expansion for suspected impaired fetal growth.
Search strategy: We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register. Date of last search: December 1999.
Selection criteria: Randomized or quasi-randomized trials of plasma volume expansion compared to no plasma volume expansion in women with suspected impaired fetal growth.
Data collection and analysis: Trial quality was assessed.
Main results: No studies were included.
Reviewer's conclusions: There is not enough evidence to evaluate the use of plasma volume expansion for suspected impaired fetal growth.
Conflict of interest statement
None known.
Similar articles
-
Plasma volume expansion for treatment of women with pre-eclampsia.Cochrane Database Syst Rev. 2000;1999(2):CD001805. doi: 10.1002/14651858.CD001805. Cochrane Database Syst Rev. 2000. PMID: 10796272 Free PMC article.
-
Maternal nutrient supplementation for suspected impaired fetal growth.Cochrane Database Syst Rev. 2000;2003(2):CD000148. doi: 10.1002/14651858.CD000148. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2003;(1):CD000148. doi: 10.1002/14651858.CD000148. PMID: 10796156 Free PMC article. Updated.
-
Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003402. doi: 10.1002/14651858.CD003402.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2018 Nov 15;11:CD003402. doi: 10.1002/14651858.CD003402.pub3. PMID: 16856006 Updated.
-
Maternal nutrient supplementation for suspected impaired fetal growth.Cochrane Database Syst Rev. 2003;(1):CD000148. doi: 10.1002/14651858.CD000148. Cochrane Database Syst Rev. 2003. PMID: 12535390
-
Early volume expansion for prevention of morbidity and mortality in very preterm infants.Cochrane Database Syst Rev. 2001;(4):CD002055. doi: 10.1002/14651858.CD002055. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2004;(2):CD002055. doi: 10.1002/14651858.CD002055.pub2. PMID: 11687136 Updated.
Cited by
-
Intrauterine Growth Restriction. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015/080, October 2016).Geburtshilfe Frauenheilkd. 2017 Nov;77(11):1157-1173. doi: 10.1055/s-0043-118908. Epub 2017 Nov 27. Geburtshilfe Frauenheilkd. 2017. PMID: 29375144 Free PMC article.
-
Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews.Cochrane Database Syst Rev. 2017 Aug 8;8(8):CD012077. doi: 10.1002/14651858.CD012077.pub2. Cochrane Database Syst Rev. 2017. PMID: 28786098 Free PMC article.
-
Immediate versus deferred delivery of the preterm baby with suspected fetal compromise for improving outcomes.Cochrane Database Syst Rev. 2016 Jul 12;7(7):CD008968. doi: 10.1002/14651858.CD008968.pub3. Cochrane Database Syst Rev. 2016. PMID: 27404120 Free PMC article.
-
Nutritional intra-amniotic therapy increases survival in a rabbit model of fetal growth restriction.PLoS One. 2018 Feb 21;13(2):e0193240. doi: 10.1371/journal.pone.0193240. eCollection 2018. PLoS One. 2018. PMID: 29466434 Free PMC article.
-
Evidence for perinatal and child health care guidelines in crisis settings: can Cochrane help?BMC Public Health. 2010 Mar 29;10:170. doi: 10.1186/1471-2458-10-170. BMC Public Health. 2010. PMID: 20350326 Free PMC article.
References
References to studies excluded from this review
Bsteh 1995 {published data only}
-
- Bsteh M, Tews G, John D. Hemodilution in treatment of intrauterine dystrophy [Haemodilution bei der behandlung der intrauterinen dystrophie]. Geburtshilfe und Frauenheilkunde 1995;55:83‐6. - PubMed
Heilmann 1991 {published data only}
-
- Heilmann L, Lorch E, Hojnacki B, Muntefering H, Forster H. Accumulation of two different hydroxyethyl starch preparations in the placenta after hemodilution in patients with fetal intrauterine growth retardation or pregnancy hypertension. Infusionstherapie 1991;18:236‐43. - PubMed
Heilmann 1993 {published data only}
-
- Heilmann L, Tempelhoff G‐Fv. Doppler sonographic results following hemodilution therapy. Zeitschrift fur Geburtshilfe und Perinatologie 1993;197:43‐7. - PubMed
-
- Tempelhoff G‐Fv, Heilman L. The effect of plasma volume expansion on the uteroplacental perfusion. Clinical Hemorheology 1993;13:729‐36.
Additional references
Bernstein 2000
-
- Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among very low birth weight infants with intrauterine growth restriction. The Vermont Oxford Network. American Journal of Obstetrics and Gynecology 2000;182:198. - PubMed
Clarke 2000
-
- Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1 [updated June 2000]. In: Review Manager (RevMan) [Computer program]. Version 4.1. Oxford, England: The Cochrane Collaboration, 2000.
Lin 1998
-
- Lin C, Santolaya‐Forgas J. Current concepts of fetal growth restriction: Part 1. Causes, classification, and pathophysiology. Obstetrics & Gynecology 1998;92(6):1044‐55. - PubMed
Resnik 2002
-
- Resnik R. Intrauterine growth restriction. Obstetrics & Gynecology 2002;99(3):490‐6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
